Two MRI Methods for Measuring Liver Stiffness in Cirrhosis and Portal Hypertension
Compares two MRI imaging methods for estimating pressure in liver blood vessels in cirrhosis.
Plain-language title generated from the registry record
Registry title: 3D-MRE and 2D-MRE for Assessing Cirrhosis and Portal Hypertension
Key facts
- Where
- Shenyang, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with confirmed cirrhosis who had two types of MRI liver stiffness scans (3D-MRE and 2D-MRE) and a portal pressure measurement (HVPG) close together.
- Age
- Over 18 years, up to 75 years
- Sex
- All sexes can join
- Disease stage
- Confirmed cirrhosis (by laboratory tests, imaging and clinical symptoms)
- Earlier treatment
- Must have had 3D-MRE and 2D-MRE within 1 month before the HVPG measurement. Must not have had previous liver or spleen surgery.
Main reasons for not taking part
- Any previous liver or spleen surgery
- Liver cancer or chronic acute liver failure
- Acute portal hypertension
- Unreliable HVPG, 3D-MRE or 2D-MRE results due to technical reasons
- Liver interventional therapy between the HVPG and MRE
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT06205992, who can take part
Where in China
- Shengjing Hospital Of China Medical UniversityShenyang, ChinaContact: Yu Shi, MDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Shengjing Hospital
- Trial code
- NCT06205992
- Record updated
- 9 February 2026
- Original description
How to construct a novel, non-invasive, accurate, and convenient method to achieve prediction of hepatic venous pressure gradient (HVPG) is an important general problem in the management of portal hypertension in cirrhosis. We plan to compare the ability of three demensional-magnetic resonance elastography (3D-MRE) to two demensional-magnetic resonance elastography (2D-MRE) to establish a risk stratification system and perform tailored management for portal hypertension in cirrhosis.Read full original descriptionShow less
Three-dimensional MR Elastography and Two-dimensional MR Elastography for Assessing Cirrhosis and Portal Hypertension：A Prospective Multicenter Study
How to construct a novel, non-invasive, accurate, and convenient method to achieve prediction of hepatic venous pressure gradient (HVPG) is an important general problem in the management of portal hypertension in cirrhosis. We plan to compare the ability of three demensional-magnetic resonance elastography (3D-MRE) to two demensional-magnetic resonance elastography (2D-MRE) to establish a risk stratification system and perform tailored management for portal hypertension in cirrhosis.
Inclusion: age > 18 years old; confirmed cirrhosis (laboratory, imaging and clinical symptoms); with 3D-MRE and 2D-MRE within 1 month prior to HVPG measurement; written informed consent.
Exclusion: any previous liver or spleen surgery; with liver interventional therapy between HVPG and MRE; liver cancer; chronic acute liver failure; acute portal hypertension; unreliable HVPG, 3D-MRE or 2D-MRE results due to technical reasons.